Clinical Trial Update: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tocilizumab (RoActemra/Actemra) in ankylosing spondylitis patients who failed NSAIDs was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Spondylitis, Ankylosing | Phase 3 | Status: TERMINATED | Results posted: 2013-02-11